23 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
would have expressly granted the FDA authority to regulate LDTs under a risk-based framework; and the Verified Innovative Testing in American … ”), which would have expressly granted the FDA authority to regulate LDTs under a risk-based framework; and the Verified Innovative Testing in American
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
to regulate LDTs under a risk-based framework; and the Verified Innovative Testing in American Laboratories Act of 2020 (the “VITAL Act”), which would … ; and the Verified Innovative Testing in American Laboratories Act of 2020 (the “VITAL Act”), which would have assigned LDTs to regulation solely under
8-K
EX-99.1
0el0ayhhe6q
5 Mar 24
Increasing physician interest, newly approved reimbursement code driving growth
5:26pm
8-K
qyukm3bsq7p
5 Dec 23
Departure of Directors or Certain Officers
8:45am
8-K
EX-99.1
6ws uax4h2grpq9h49a
5 Dec 23
Departure of Directors or Certain Officers
8:45am
DRS
uu6yd1861iuepz6c7u
14 Aug 23
Draft registration statement
12:00am
DEF 14A
nh8x n15e5qnaj
1 May 23
Definitive proxy
2:55pm
PRE 14A
4b5 6w1x6xj
19 Apr 23
Preliminary proxy
9:56pm
10-K
ac6auq1p
31 Mar 23
Annual report
3:40pm
8-K
EX-99.1
zbpun9inp0m
15 Dec 22
Other Events
1:26pm
8-K
EX-99.1
q28h0zzm5lrx5d5ajc
10 Nov 22
Other Events
12:52pm
424B4
7vif7a
2 Sep 22
Prospectus supplement with pricing info
3:25pm